Sotera Health (SHC) Q2 2026 earnings review
A Clean Beat-and-Raise as Nelson Labs Returns to Growth
Sotera Health delivered a pristine second quarter, punctuated by high-single-digit revenue growth and a raised full-year outlook. The most significant development was the turnaround at Nelson Labs, which reversed its revenue decline. Crucially, the company hit its long-term net leverage target of 3.0x and eliminated the final remnants of its private equity sponsor ownership. The balance sheet is de-risked, the core sterilization business is humming, and earnings are accelerating.
🐂 Bull Case
After quarters of dragging down consolidated results, Nelson Labs revenue grew 6.3% YoY. The return of core lab testing volumes removes the largest top-line headwind.
Net leverage successfully reached the 3.0x target. Combined with a recent term loan repricing saving $3.5M annually, Sotera's cash flow is increasingly flowing directly to equity holders.
🐻 Bear Case
Nordion's impressive H1 growth (driven by Cobalt-60 harvest timing) sets up a steep deceleration in the second half of the year, which is already priced into the full-year guidance.
Despite returning to revenue growth, Nelson Labs segment income was nearly flat YoY (+0.6%), highlighting margin compression from elevated operating costs.
⚖️ Verdict: 🟢
Bullish. Management is executing flawlessly on its long-term plan. The balance sheet is repaired, pricing power remains intact, and guidance was confidently raised.
Key Themes
Nelson Labs: From Laggard to Contributor
Reversing. Nelson Labs flipped from a persistent top-line drag to a growth contributor, delivering 6.3% YoY revenue growth ($60.7M). This confirms management's prior signaling that the headwind from the declining Expert Advisory Services business has finally washed through the comparables, allowing core lab testing growth to shine.
Debt and Sponsor Overhangs Cleared
Accelerating. The company achieved its long-stated net leverage target of 3.0x, down drastically from 3.7x at the end of 2024. Simultaneously, the final private equity sponsor secondary offering was completed, leaving zero sponsor ownership. A repriced term loan is unlocking $3.5M in annual interest savings. The structural pressure on the stock has evaporated.
Nelson Labs Margin Reality Check
While Nelson Labs' revenue growth (+6.3%) is a positive headline, profitability tells a different story. Segment income grew a paltry 0.6% YoY. This implies segment margins contracted from 34.1% in 25Q2 to 32.2% in 26Q2. Management cited 'higher costs.' The volume is back, but the operating leverage has not followed.
Nordion's Second-Half Cliff
Decelerating. Nordion posted a fantastic 15.8% revenue increase in Q2, but investors should brace for a stark reversal. This segment is highly dependent on the lumpy timing of Cobalt-60 harvests. In prior quarters, management explicitly noted that 2026 Cobalt-60 revenues would be heavily front-loaded (40-45% of full-year revenue in H1). This mathematical reality guarantees a sharp deceleration in H2.
Sterigenics Pricing Outruns Macro Inflation
Stable. The core Sterigenics business grew 8.6% to $211.6M. Management specifically noted that top-line growth was driven by favorable pricing and improved volume/mix, which more than offset ongoing macroeconomic inflationary pressures on costs. Segment income grew 9.6%, proving the pricing power of mission-critical sterilization services remains unshakeable.
Other KPIs
Down 15% from $40.7M in 25Q2. This is the direct result of disciplined debt paydown and active refinancing over the last 12 months. This metric will continue to act as a tailwind for EPS as the repriced term loan ($3.5M annual savings) takes full effect.
Strong cash generation in Q2 supported the continued reduction of net leverage and boosted unrestricted cash and cash equivalents to $357M. Total available liquidity sits comfortably at $950M.
Guidance
Accelerating. Raised from the previous range of $1.233B - $1.251B. Implies constant currency growth of 5.25% to 6.75%. The raise reflects H1 strength in Sterigenics and the timing pull-forwards in Nordion.
Accelerating. Raised from $632M - $641M. Represents constant currency growth of 5.75% to 7.25%. The upward revision confirms that top-line momentum is effectively dropping to the bottom line despite isolated cost pressures at Nelson Labs.
Accelerating. Raised from the prior outlook of $0.93 - $1.01. The combination of higher operating income, lower interest expense, and a newly lowered tax rate outlook (27.0% - 28.0%) is compounding earnings growth.
Key Questions
Capital Allocation Pivot
Now that you have achieved the 3.0x net leverage target and the private equity sponsor is completely exited, how does the hierarchy of capital allocation shift between M&A, share buybacks, and further debt reduction?
Nelson Labs Margins
Nelson Labs returned to 6.3% revenue growth, but segment income was practically flat due to higher costs. What are the specific drivers of these costs, and what is the timeline to restore this segment's operating leverage?
X-Ray Facility Update
Can you provide an update on customer commitments for the new X-ray facility opening later this year? How much margin dilution should we model for the Sterigenics segment during the initial ramp-up phase?